by TractManager | May 1, 2024 | Emerging Technology Report
CYB003 (Cybin Inc.) is an oral deuterated psilocybin analogue proposed for use in conjunction with supportive psychotherapy for treatment of patients with moderate to severe major depressive disorder who have had an inadequate response to an antidepressant...
by TractManager | Apr 26, 2024 | Emerging Technology Report
Fidanacogene elaparvovec-dzkt (Beqvez; Pfizer Inc.) is a single-infusion gene therapy for the treatment of adults with moderate to severe hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have...
by TractManager | Apr 25, 2024 | Emerging Technology Report
The Ventura Interatrial Shunt (V-Wave Ltd.) is an investigational transcatheter interatrial shunt proposed for treatment of chronic heart failure.
by TractManager | Apr 24, 2024 | Emerging Technology Report
Rusfertide (formerly PTG-300; Protagonist Therapeutics Inc./Takeda Pharmaceutical Co. Ltd.) is a subcutaneously injected hepcidin mimetic for the treatment of erythrocytosis associated with polycythemia vera.
by TractManager | Apr 23, 2024 | Emerging Technology Report
Letetresgene autoleucel is an investigational autologous engineered T-cell therapy for the treatment of HLA-A*02 positive patients with advanced synovial sarcoma expressing the NY-ESO-1 antigen.
Recent Comments